Risultati per: Papilloma virus

Pandemia resta emergenza internazionale di sanità pubblica

Objectives
To examine the reported incidence and features of disseminated varicella zoster virus (VZV) infection following live attenuated herpes zoster vaccine live (ZVL: Zostavax, Merck) in immunocompromised people in Australia.

Design and setting
ZVL was funded in 2016 in Australia for people aged 70 years, with a catch-up programme for those 71–79 years. From 2016 to 2020, three deaths due to disseminated vaccine-strain VZV infection occurred following inadvertent ZVL administration in individuals with varying levels of immunocompromise. This descriptive study examined 4 years of national surveillance data reported to the Therapeutic Goods Administration’s Adverse Event Monitoring System (AEMS). Denominator data for rates were from doses recorded in the Australian Immunisation Register.

Participants
Individuals vaccinated between 1 November 2016 and 31 December 2020 who experienced adverse event(s) following immunisation (AEFI) after ZVL recorded in the AEMS.

Primary and secondary outcome measures
Rates and outcomes of confirmed (Oka strain positive) or probable disseminated VZV infection, and inadvertent administration of ZVL in immunocompromised individuals.

Results
854 AEFI were reported from 1 089 966 doses of ZVL administered (78.4 per 100 000 doses). Of those, 14 were classified as confirmed (n=6, 0.55 per 100 000) or probable (n=8) disseminated VZV infection. The confirmed cases were all hospitalised, and most (5/6) were immunocompromised; three cases died. Thirty-seven individuals were reported as vaccinated despite a contraindication due to immunocompromise (3.4 per 100 000), with 12/37 (32%) hospitalised.

Conclusions
Disseminated VZV is potentially life-threatening and occurs mostly in those with severe immunocompromise. Inadvertent administration of ZVL to immunocompromised individuals has occurred despite initial provider guidance and education. Multiple additional strategies to assist providers to identify contraindications have been implemented to prevent adverse outcomes.

Annals of Internal Medicine, Ahead of Print.

Studio Usa, supporto di ossigeno e ricovero in terapia intensiva

Ecdc:’Si valuti invito a non volare’. Oms, Kraken non è più grave

New England Journal of Medicine, Volume 387, Issue 25, December 2022.

Objectives
Respiratory syncytial virus (RSV) is one of the most important causes of lower respiratory tract illnesses. In this study, we examined the number and severity of RSV infections among adult patients. The underlying diseases and background information of patients with RSV were examined and compared with the patients with influenza.

Design
Retrospective cohort study.

Setting
Patients receiving tertiary care services in Kuopio University Hospital (KUH) district in Eastern Finland.

Participants
725 patients (152 with RSV infection and 573 with influenza) treated in KUH between November 2017 and May 2018.

Primary and secondary outcome measures
Hospitalisation and mortality.

Results
Compared with influenza, RSV caused a more serious disease in terms of hospitalisation (84.2% vs 66.0%, p

New England Journal of Medicine, Ahead of Print.

La conferma da studio GB ma basta lavare mani e prodotti freschi

Con arrivo dei mesi più freddi. BQ1.1sta rimpiazzando BA5

Objectives
To support the Zika virus (ZIKV) Individual Participant Data (IPD) Consortium’s efforts to harmonise and analyse IPD from ZIKV-related prospective cohort studies and surveillance-based studies of pregnant women and their infants and children; we developed and disseminated a metadata survey among ZIKV-IPD Meta-Analysis (MA) study participants to identify and provide a comprehensive overview of study-level heterogeneity in exposure, outcome and covariate ascertainment and definitions.

Setting
Cohort and surveillance studies that measured ZIKV infection during pregnancy or at birth and measured fetal, infant, or child outcomes were identified through a systematic search and consultations with ZIKV researchers and Ministries of Health from 20 countries or territories.

Participants
Fifty-four cohort or active surveillance studies shared deidentified data for the IPD-MA and completed the metadata survey, representing 33 061 women (11 020 with ZIKV) and 18 281 children.

Primary and secondary outcome measures
Study-level heterogeneity in exposure, outcome and covariate ascertainment and definitions.

Results
Median study sample size was 268 (IQR=100, 698). Inclusion criteria, follow-up procedures and exposure and outcome ascertainment were highly heterogenous, differing meaningfully across regions and multisite studies. Enrolment duration and follow-up for children after birth varied before and after the declaration of the Public Health Emergency of International Concern (PHEIC) and according to the type of funding received.

Conclusion
This work highlights the logistic and statistical challenges that must be addressed to account for the multiple sources of within-study and between-study heterogeneity when conducting IPD-MAs of data collected in the research response to emergent pathogens like ZIKV.

Lanciata da Sanofi con pediatri, neonatologi,esperti prevenzione

This study uses electronic medical record data to describe monkeypox infections after a single dose of Modified Vaccinia Ankara-Bavarian Nordic vaccine, a live, nonreplicating vaccine indicated for prevention of smallpox and monkeypox infection in adults.

Mille infettivologi al XXI congresso Simit a Roma

New England Journal of Medicine, Ahead of Print.

Annals of Internal Medicine, Volume 175, Issue 12, Page 1639-1647, December 2022.